Valuation: KYORIN Pharmaceutical Co., Ltd.

Market Cap 62.85B 397M 356M 329M 298M 558M 37.83B 564M 3.94B 1.57B 19.8B 1.49B 1.46B P/E 2027 *
40.5x
P/E 2028 * 38.8x
Enterprise Value 62.85B 397M 356M 329M 298M 558M 37.83B 564M 3.94B 1.57B 19.8B 1.49B 1.46B EV / Sales 2027 *
0.5x
EV / Sales 2028 * 0.6x
Free-Float
60.02%
Yield 2027 *
2.29%
Yield 2028 * 2.29%
10-01 Daito, Meiji Seika Pharma, DBJ to Form JV to Take Over Kyorin Pharmaceutical's Generic Drug Business MT
08-03 KYORIN Pharmaceutical Co., Ltd. Commences Promotion Activities For Allergic Conjunctivitis Treatment Alesion Eyelid Cream 0.5% CI
07-13 KYORIN Pharmaceutical Co., Ltd. and Santen Pharmaceutical Co., Ltd. Enter Joint Marketing Agreement for Allergic Conjunctivitis Treatment Alesion Cream 0.5% CI
05-12 KYORIN Pharmaceutical Co., Ltd. Provides Cash Dividend Guidance for the Second Quarter-End and Year-End of Fiscal Year Ending March 31, 2027 CI
05-12 Kyorin Pharmaceutical Co., Ltd. Announces Directorate and Executive Changes, Effective June 19, 2026 CI
05-12 KYORIN Pharmaceutical Co., Ltd. Announces Year-End Dividend for the Fiscal Year Ended March 31, 2026, Payable on June 4, 2026 CI
05-12 Kyorin Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Half and Full Fiscal Year Ending March 31, 2027 CI
04-27 Japanese Stocks Climb as Iran's Plan to Reopen Strait Boosts Sentiment MT
04-27 Kyorin Pharma Signs MOU to Transfer Generic Drug Business to Daito Group MT
04-24 Daito Pharmaceutical Co Ltd Signs MOU with Kyorin Pharmaceutical Co Ltd to Transfer Generic Drug Business to New Joint Venture CI
04-24 Daito Pharmaceutical Co.,Ltd., Development Bank of Japan Inc. and Meiji Seika Pharma Co., Ltd signed a Memorandum of Understanding to acquire KYORIN Rimedio Co., Ltd from KYORIN Pharmaceutical Co., Ltd.. CI
03-31 Kyorin Pharmaceutical Co Ltd - Kyorin enters into license agreement with Biodol for novel neuropathic pain treatment RE
03-25 Kyorin Pharmaceutical Co., Ltd. and Johnson & Johnson Enter Exclusive Distribution and Promotion Agreement for Sirturo CI
1 day-0.91%
1 week-4.16%
Current month-1.90%
1 month-2.17%
3 months-11.00%
6 months-30.11%
Current year-29.47%
1 week 1,081
Extreme 1081
1,151
1 month 1,046
Extreme 1046
1,151
Current year 1,046
Extreme 1046
1,725
1 year 1,046
Extreme 1046
1,725
3 years 1,046
Extreme 1046
1,880
5 years 1,046
Extreme 1046
1,924
10 years 1,046
Extreme 1046
2,829
Manager TitleAgeSince
Chief Executive Officer 59 01/04/2023
Director of Finance/CFO 56 01/04/2023
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 59 01/06/2011
Director/Board Member 78 01/06/2013
Director/Board Member 66 01/04/2015
Change 5-day change 1-year change 3-year change Capi.($)
-1.19%-4.16%-21.85%-37.49% 404M
+0.50%+1.38%+57.09%+129.96% 1,143B
+0.86%+5.14%+45.00%+86.15% 647B
-0.14%+0.42%+25.69%+105.85% 506B
-0.05%+1.73%+52.74%+67.74% 384B
-0.63%-5.97%+61.93%+37.06% 350B
+0.34%+1.84%+30.70%+54.27% 293B
-0.45%+1.19%+2.89%+26.08% 265B
+0.87%+3.08%+54.69%+72.74% 242B
+0.08%+3.67%+35.05%+107.78% 197B
Average +0.05%+0.72%+34.39%+65.02% 402.79B
Weighted average by Cap. +0.25%+0.71%+44.49%+89.00%

Financials

2027 *2028 *
Net sales 125B 788M 707M 653M 592M 1.11B 75.01B 1.12B 7.81B 3.11B 39.25B 2.96B 2.89B 104B 659M 591M 546M 495M 924M 62.72B 936M 6.53B 2.6B 32.82B 2.47B 2.42B
Net income 1.55B 9.8M 8.79M 8.13M 7.36M 13.75M 933M 13.92M 97.16M 38.7M 488M 36.76M 35.99M 1.62B 10.24M 9.19M 8.49M 7.69M 14.37M 975M 14.54M 102M 40.45M 510M 38.42M 37.61M
Net Debt - -
Projected Income Statement - Annual - KYORIN Pharmaceutical Co., Ltd.
Logo KYORIN Pharmaceutical Co., Ltd.
Kyorin Pharmaceutical Co Ltd, formerly Kyorin Holdings Inc, is a Japan-based company mainly engaged in the pharmaceuticals business. The Pharmaceuticals segment is mainly engaged in the manufacture, purchase, sales and testing of pharmaceutical products, the purchase of raw materials for pharmaceuticals, the evaluation of technologies, the inspection, analysis and negotiation of license affiliations, the operations related to clinical trials and information gathering such as searching for drug discovery seeds, as well as the drug candidate compound discovery research and compound evaluation business. The Company also conducts the diagnostic businesses and verifies and creates research targets that are directly linked to drug discovery.
Employees
1,982
Date Price Change Volume
29/10/26 ¥1,081.00 -1.19% 21,600
28/10/26 ¥1,094.00 -1.53% 154,800
27/10/26 ¥1,111.00 -1.94% 140,900
26/10/26 ¥1,133.00 +0.71% 85,400
23/10/26 ¥1,125.00 -0.53% 148,400
Trader
-
Investor
Global
-
Quality
ESG MSCI
BB
MarketScreener Ratings - KYORIN Pharmaceutical Co., Ltd.
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
1
Last Close Price
1,094.00JPY
Average target price
1,100.00JPY
Spread / Average Target
+0.55%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - KYORIN Pharmaceutical Co., Ltd.
  1. Stock Market
  2. Stocks
  3. 4569 Stock